Access the industry's premier life science partnering event, BioPharm America™ in Boston September 26–27, 2017, to connect with strategic partners and get your innovation funded. No other event combines high-caliber partnering with intensive networking in an intimate setting.
Home » Partnering & Drug Development » How can startup companies get noticed by potential investors and partners?
Where are they now? For Virvio, it’s all about visibility
When Virvio participated in BioPharm America™’s Startup Day pitch contest in 2016, the company had been ope...
Other content in this Stream
ChinaBio® Partnering Forum 2017: HitGen aids China drug discovery with DNA library
Wei Chen, head of R&D for Chengdu-based HitGen describes to Scrip’s Brian Yang how the Chinese startup partners with multinationals to speed up new drug development in China, and planned IND filing fo
ChinaBio® Partnering Forum 2017: Sirnaomics prioritizes China in parallel with US RNAi development
Alan Y. Lu, Executive VP of Sirnaomics, discusses with Scrip’s Brian Yang how the US-China hybrid looks to develop RNAi therapies simultaneously in the two countries. RNAi is relatively new in China,
ChinaBio® Partnering Forum 2017: China's HEC Pharm enters America with novel IPF treatment
Tommy Lin, head of Business Development and Global Licensing for HEC Pharm outlines for Scrip’s Brian Yang how the Chinese domestic drug company looks to develop its liver drug in the US. On May 2, t
ChinaBio® Partnering Forum 2017: China's EpimAb hunts for novel biologics with funding, partnership
Dr. Wu Chengbin, CEO and founder of Shanghai-based EpimAb Biotherapeutics discusses with Scrip’s Brian Yang how the startup's preparatory platform will develop next-generation bispecific antibodies.
ChinaBio® Partnering Forum 2017: ConSynance tests waters in China with differentiated NASH asset
Dr. Shuang Liu, president and co-founder of upstate New York-based ConSynance Therapeutics discusses with Scrip’s Brian Yang the startup's plan to develop and commercialize its multiple assets in vari
ChinaBio® Partnering Forum 2017: Roche looks to real-world data and IT to drive partnering in China
Mark Noguchi, Global Head, Alliance and Asset Management at Roche discusses with Scrip’s Brian Yang the Swiss biotech's plan to tap into emerging IT for partnering opportunities in China. Roche has be
Where are they now? EpiAxis Therapeutics channels successes into scientific and business development
EpiAxis Therapeutics is channeling its success at BioPharm America™’s Startup Day into success at the business and scientific levels. Since finishing first for best “investment pitch quality and...
ChinaBio® Partnering Forum 2017: Funding drug development in China through VCs and partnerships
Western and China companies are leveraging the significant funding and support available in China to develop their assets more cost effectively and efficiently. 2016 set another record in VC funds rai
ChinaBio® Partnering Forum 2017: Rapid change: Good times for pharma?
Everything in China seems to be on the fast track. This is especially true in the pharma industry, where new announcements affecting regulations, pricing, and reimbursement are occurring on nearly a d
Biotech Startups: Land and conduct a successful investor meeting
Biotech startup companies face many challenges, but one of the most common is landing and conducting meetings with potential investors. The following are pieces of advice from investors on what...
Where are they now? Cocoon Biotech planning tox studies
Recognition from a high profile organization like the BioPharm America™ conference has been tremendous for Cocoon,” Ailis Tweed-Kent, MD, founder and CEO of Cocoon Biotech says. Winning the...
Where are they now? For Virvio, it’s all about visibility
When Virvio participated in BioPharm America™’s Startup Day pitch contest in 2016, the company had been operational less than one year. It had three employees and was operating under grants from...
Where to start: How to gain a foothold in the China biopharmaceutical market
The China pharmaceutical market has come of age. With record breaking investments in innovative companies, support from the CFDA, and new product approvals pending, China has entered a new age as...
BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs
Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s Mike Ward how his company can help biotechs and pharma firms cut the cost of Phase I and IIa t
BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets
With the Latin American vaccines market forecast to more than quadruple in size from just over USD 150 million to 2015 to just under USD 700 million in 2020, opportunities abound for both homegrown bu
Tissue regeneration: A vital area within regenerative medicine
Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence and Nancy Dvorin, Executive Editor, In Vivo Cell and gene therapies often get the lion’s...
Bruce Levine is a man you can thank for your future cell therapy
To call Bruce Levine, PhD, an innovator in the cell and gene therapy space is a gross understatement. He is known for his groundbreaking work in the development and use of synthetic immune cells...
BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline
Thomas Zioncheck, global head of business development for neuroscience, ophthalmology, and research tools and technology at Genentech, talks to Scrip about the company's early-stage partnering strateg
BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice
Over the last decade Ergomed has evolved from a contract research organization into a clinical-stage drug development company. Chief business officer Andrew Mackie tells Scrip more about this transfor
BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities